首页> 外国专利> MICRORNA-BASED THERAPY TARGETED AGAINST LCP-1 POSITIVE CANCERS

MICRORNA-BASED THERAPY TARGETED AGAINST LCP-1 POSITIVE CANCERS

机译:针对LCP-1阳性肿瘤的基于微小RNA的治疗

摘要

The present invention relates to a panel of miRNAs comprising miR-16-5p, miR-23a-5p, miR-125b-5p, miR-145-5p, miR-146a-3p, miR-181c-5p, miR-218-5p, miR-495-3p, let-7b-5p, and further comprising one or more miRNAs selected from the group consisting of miR-30a-5p, miR-30b-5p, miR-30c-5p, miR-30d-5p, miR-30e-5p, miR-194-5p, miR-302a-3p, miR-302a-5p, miR-335-3p, miR-335-5p, miR-367- 3p, miR-373-3p, and miR-885-5p, and to extracellular vesicles (EVs), e.g. of stem cell origin, loaded with the panel of miRNAs. The present invention further provides the panel or EVs for use in a method of treating LCP-1 positive cancer in a patient.
机译:本发明涉及一组miRNA,其包含miR-16-5p,miR-23a-5p,miR-125b-5p,miR-145-5p,miR-146a-3p,miR-181c-5p,miR-218- 5p,miR-495-3p,let-7b-5p,并进一步包含一种或多种选自miR-30a-5p,miR-30b-5p,miR-30c-5p,miR-30d-5p的miRNA。 ,miR-30e-5p,miR-194-5p,miR-302a-3p,miR-302a-5p,miR-335-3p,miR-335-5p,miR-367-3p,miR-373-3p和miR-885-5p,以及细胞外囊泡(EV),例如含有大量miRNA的干细胞来源。本发明进一步提供了用于治疗患者中LCP-1阳性癌症的方法的面板或电动汽车。

著录项

  • 公开/公告号WO2020030750A1

    专利类型

  • 公开/公告日2020-02-13

    原文格式PDF

  • 申请/专利权人 THERAMIR LTD;

    申请/专利号WO2019EP71341

  • 发明设计人 PROKOPI MARIANNA;

    申请日2019-08-08

  • 分类号C12N15/113;A61K31/7105;A61K9/50;

  • 国家 WO

  • 入库时间 2022-08-21 11:13:29

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号